Well cover effectiveness, side effects, cost, and practical considerations to help you make an informed decision with your doctor
Glow Shakes are beneficial for everyone
N Engl J Med 2025;393:1796-1806 [9] Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial, December 2025: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company [10] Fourth High-level Meeting of the UN General Assembly on the prevention and control of NCDs and the promotion of mental health and wellbeing (HLM4), September 2025: [11] Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study, November 2025: Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study - GOV.UK [12] Non-Traditional Channels: The Compounded GLP-1 Market

After 52 weeks, participants who took 36 milligrams of orforglipron saw a key blood sugar marker reduce by nearly 2 percent, while those who received 14 milligrams of oral semaglutide saw levels drop by nearly 1.5 percent